Immunosyn CEO Hid FDA Hold From Investors, Jury Told

Loeb & Loeb partner Corey Rubenstein is quoted in this article on his client’s intentions in regards to disclosures to investors. The article discusses the case against Stephen Ferrone, the CEO of publicly traded biopharmaceutical company Immunozyn Corp., in which he was accused of hiding regulators’ concerns about the company’s drug from investors in order to keep stock prices high.

Click here to read the article on Law360’s website.